F-Tryptophan PET/CT in Human Cancers

Inclusion Criteria

• •Age ≥18 years.
• •Targeted lesion (tumor) is at least 1 cm in diameter as shown by clinical imaging.
• •Patient is able to lie in the PET/CT scanner for at least 70 minutes while undergoing scanning.
• •Women of childbearing potential must not be pregnant or breastfeeding.
• •Recent anatomic imaging with visible disease (tumor) for comparison with the PET/CT. .
• •Physical exam within 28 days of PET imaging, CBC and Multiphasic (including electrolytes, BUN, creatinine, total bilirubin, AST and ALT) within 14 days.
• •Patients must sign an informed consent indicating that they are aware of the investigational nature of this study.
• •\- Clinical and MRI diagnosis of an intracranial lesion suspicious for a brain tumor, including gliomas or metastatic brain tumors; primary, residual, or recurrent brain tumors (judged by clinical imaging) will qualify.
• •Histopathologically confirmed, well-differentiated metastatic neuroendocrine tumor.
• •ECOG performance status of 2 or better.
• •Patients receiving stable-dose somatostatin analogs (SSAs, long-acting release \[LAR\], depot) for \>3 months before enrollment may be enrolled on the study, but such treatment is not required.
• •Clinical and radiological diagnosis of a breast cancer
• •ECOG performance status of 2 or better.
• •Histologically confirmed colorectal cancer, which is located in the rectum.
• •ECOG performance status of 2 or better.